<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03638635</url>
  </required_header>
  <id_info>
    <org_study_id>17-2725</org_study_id>
    <nct_id>NCT03638635</nct_id>
  </id_info>
  <brief_title>Standard Bupivacaine vs Liposomal Bupivacaine in Colorectal Patients</brief_title>
  <official_title>TAP Blocks Performed With Bupivacaine Versus Liposomal Bupivacaine in Colorectal Surgery Patients: A Prospective, Cluster Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inova Health Care Services</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inova Health Care Services</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The transversus abdominis plane (TAP) block can be used to reduce pain in patients who get
      abdominal surgery. TAP blocks are given with a local anesthetic. The purpose of this study is
      to compare pain medication usage after surgery between two different types of local
      anesthetic: liposomal bupivacaine and standard bupivacaine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pain control is a factor that is central to the surgical patient's postoperative experience.
      Opioid pain medications are a mainstay of postoperative pain management. However, these have
      several adverse effects.

      Multimodal pain regimens to minimize opioid use have become central to enhanced recovery
      after surgery (ERAS) protocols. The transversus abdominis plane (TAP) block is one
      intervention that contributes to this regimen. Traditionally, TAP blocks are performed with
      local anesthetics such as bupivacaine. More recently, these have also been performed with
      liposomal bupivacaine, whose duration of action is much greater than regular bupivacaine (96
      hours versus 8-9 hours, respectively).

      In this study, postoperative opioid usage will be compared between patients receiving regular
      bupivacaine and liposomal bupivacaine.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of personnel available to complete study.
  </why_stopped>
  <start_date type="Actual">May 14, 2018</start_date>
  <completion_date type="Actual">January 16, 2019</completion_date>
  <primary_completion_date type="Actual">January 16, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants are randomized to receive either standard bupivacaine or liposomal bupivacaine.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>The participant and the floor nursing staff recording pain scores will be blinded to the assigned intervention.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>In-hospital Postoperative Opioid Consumption</measure>
    <time_frame>up to postoperative day 3 at 1 pm</time_frame>
    <description>Daily overall opioid use recorded as morphine equivalents</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Score</measure>
    <time_frame>Approximately every 6 hours through postoperative day 3 by 1 pm</time_frame>
    <description>Recorded on a scale of 0 (No pain) to 10 (Worst possible pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Patient Mobilization</measure>
    <time_frame>From time of surgery until time of first patient ambulation post op. Assessed until date of discharge (usually up to 4 days after surgery).</time_frame>
    <description>Number of days from day of surgery until patient mobilization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Return of Bowel Function</measure>
    <time_frame>From time of surgery until first time patient passes gas or stool per rectum or into ostomy bag. Assessed until date of discharge (usually up to 4 days after surgery).</time_frame>
    <description>Number of days from time of surgery until return of bowel function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Clear Liquid Diet</measure>
    <time_frame>From time of surgery until first time patient tolerates clear liquids without nausea or vomiting. Assessed until date of discharge (usually up to 4 days after surgery).</time_frame>
    <description>Number of days from time of surgery until patient tolerates clear liquid diet</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Low Fiber Diet</measure>
    <time_frame>From time of surgery until first time patient tolerates a low fiber diet without nausea or vomiting. Assessed until date of discharge (usually up to 4 days after surgery).</time_frame>
    <description>Number of days from day of surgery until patient tolerates low fiber diet</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay</measure>
    <time_frame>Date of surgery to date of discharge (usually up to 4 days after surgery).</time_frame>
    <description>Total postoperative hospital stay in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital Antiemetic Use</measure>
    <time_frame>Time of transfer to post operative suite to time of discharge (usually up to 4 days after surgery).</time_frame>
    <description>Amount of ondansetron patient required postoperatively during hospital stay, in milligrams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>Within 30 days of surgery</time_frame>
    <description>Patient suffered a complication (infection, small bowel obstruction, dehydration, deep vein thrombosis/pulmonary embolism, anastomotic leak, cardiac arrest, stroke, sepsis) after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmissions</measure>
    <time_frame>Within 30 days of hospital discharge</time_frame>
    <description>Patient readmitted to hospital after discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Within 30 days of surgery</time_frame>
    <description>Patient death after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization Costs</measure>
    <time_frame>From date of this surgical admission to date of this surgical discharge (usually up to 4 days after surgery).</time_frame>
    <description>Total hospitalization costs per patient per this surgical encounter</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Opioid Use</condition>
  <condition>Pain, Postoperative</condition>
  <condition>Colectomy</condition>
  <condition>Colorectal Surgery</condition>
  <arm_group>
    <arm_group_label>Standard Bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard (0.25% bupivacaine) bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine Liposome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liposomal bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>Abdominal injection of bupivacaine into fascial layer.</description>
    <arm_group_label>Standard Bupivacaine</arm_group_label>
    <other_name>Marcaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine liposome</intervention_name>
    <description>Abdominal injection of bupivacaine liposome into fascial layer.</description>
    <arm_group_label>Bupivacaine Liposome</arm_group_label>
    <other_name>Exparel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  Undergoing elective colectomy by surgeons of Fairfax Colon and Rectal Surgery

        Exclusion Criteria:

          -  Allergic to local anesthetics

          -  Unable to provide consent

          -  Pregnant

          -  On opioids at home chronically (Patients previously on a regular opioid regimen would
             need to be opioid-free for a period of 1 year for inclusion in the study)

          -  Undergoing emergent operations

          -  Undergoing loop ileostomy reversal

          -  Undergoing abdominoperineal resection, pelvic exenteration, or perineal rectal
             prolapse repairs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald Colvin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inova Health Care System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fairfax Colon &amp; Rectal Surgery, Alexandria Office</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <zip>22304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairfax Colon &amp; Rectal Surgery, Fairfax-Prosperity Office</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairfax Colon &amp; Rectal Surgery, Fair Oaks Office</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Medical Campus</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairfax Colon &amp; Rectal Surgery, Loudoun Office</name>
      <address>
        <city>Lansdowne Town Center</city>
        <state>Virginia</state>
        <zip>20176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairfax Colon &amp; Rectal Surgery, Reston Office</name>
      <address>
        <city>Reston</city>
        <state>Virginia</state>
        <zip>20190</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rafi AN. Abdominal field block: a new approach via the lumbar triangle. Anaesthesia. 2001 Oct;56(10):1024-6.</citation>
    <PMID>11576144</PMID>
  </reference>
  <reference>
    <citation>Young MJ, Gorlin AW, Modest VE, Quraishi SA. Clinical implications of the transversus abdominis plane block in adults. Anesthesiol Res Pract. 2012;2012:731645. doi: 10.1155/2012/731645. Epub 2012 Jan 19.</citation>
    <PMID>22312327</PMID>
  </reference>
  <reference>
    <citation>Rashid A, Gorissen KJ, Ris F, Gosselink MP, Shorthouse JR, Smith AD, Pandit JJ, Lindsey I, Crabtree NA. No benefit of ultrasound-guided transversus abdominis plane blocks over wound infiltration with local anaesthetic in elective laparoscopic colonic surgery: results of a double-blind randomized controlled trial. Colorectal Dis. 2017 Jul;19(7):681-689. doi: 10.1111/codi.13578.</citation>
    <PMID>27943522</PMID>
  </reference>
  <reference>
    <citation>Oh TK, Yim J, Kim J, Eom W, Lee SA, Park SC, Oh JH, Park JW, Park B, Kim DH. Effects of preoperative ultrasound-guided transversus abdominis plane block on pain after laparoscopic surgery for colorectal cancer: a double-blind randomized controlled trial. Surg Endosc. 2017 Jan;31(1):127-134. doi: 10.1007/s00464-016-4941-7. Epub 2016 Apr 29.</citation>
    <PMID>27129571</PMID>
  </reference>
  <reference>
    <citation>Walter CJ, Maxwell-Armstrong C, Pinkney TD, Conaghan PJ, Bedforth N, Gornall CB, Acheson AG. A randomised controlled trial of the efficacy of ultrasound-guided transversus abdominis plane (TAP) block in laparoscopic colorectal surgery. Surg Endosc. 2013 Jul;27(7):2366-72. doi: 10.1007/s00464-013-2791-0. Epub 2013 Feb 7.</citation>
    <PMID>23389068</PMID>
  </reference>
  <reference>
    <citation>Favuzza J, Delaney CP. Outcomes of discharge after elective laparoscopic colorectal surgery with transversus abdominis plane blocks and enhanced recovery pathway. J Am Coll Surg. 2013 Sep;217(3):503-6. doi: 10.1016/j.jamcollsurg.2013.03.030. Epub 2013 Jun 28.</citation>
    <PMID>23810575</PMID>
  </reference>
  <reference>
    <citation>Ris F, Findlay JM, Hompes R, Rashid A, Warwick J, Cunningham C, Jones O, Crabtree N, Lindsey I. Addition of transversus abdominis plane block to patient controlled analgesia for laparoscopic high anterior resection improves analgesia, reduces opioid requirement and expedites recovery of bowel function. Ann R Coll Surg Engl. 2014 Nov;96(8):579-85. doi: 10.1308/003588414X13946184900921.</citation>
    <PMID>25350178</PMID>
  </reference>
  <reference>
    <citation>Barron KI, Lamvu GM, Schmidt RC, Fisk M, Blanton E, Patanwala I. Wound Infiltration With Extended-Release Versus Short-Acting Bupivacaine Before Laparoscopic Hysterectomy: A Randomized Controlled Trial. J Minim Invasive Gynecol. 2017 Feb;24(2):286-292. doi: 10.1016/j.jmig.2016.11.002. Epub 2016 Nov 14.</citation>
    <PMID>27856385</PMID>
  </reference>
  <reference>
    <citation>Morales R Jr, Mentz H 3rd, Newall G, Patronella C, Masters O 3rd. Use of abdominal field block injections with liposomal bupivicaine to control postoperative pain after abdominoplasty. Aesthet Surg J. 2013 Nov 1;33(8):1148-53. doi: 10.1177/1090820X13510720. Epub 2013 Nov 8.</citation>
    <PMID>24214950</PMID>
  </reference>
  <reference>
    <citation>Haas E, Onel E, Miller H, Ragupathi M, White PF. A double-blind, randomized, active-controlled study for post-hemorrhoidectomy pain management with liposome bupivacaine, a novel local analgesic formulation. Am Surg. 2012 May;78(5):574-81.</citation>
    <PMID>22546131</PMID>
  </reference>
  <reference>
    <citation>Knudson RA, Dunlavy PW, Franko J, Raman SR, Kraemer SR. Effectiveness of Liposomal Bupivacaine in Colorectal Surgery: A Pragmatic Nonsponsored Prospective Randomized Double Blinded Trial in a Community Hospital. Dis Colon Rectum. 2016 Sep;59(9):862-9. doi: 10.1097/DCR.0000000000000648.</citation>
    <PMID>27505115</PMID>
  </reference>
  <reference>
    <citation>Hutchins JL, Kesha R, Blanco F, Dunn T, Hochhalter R. Ultrasound-guided subcostal transversus abdominis plane blocks with liposomal bupivacaine vs. non-liposomal bupivacaine for postoperative pain control after laparoscopic hand-assisted donor nephrectomy: a prospective randomised observer-blinded study. Anaesthesia. 2016 Aug;71(8):930-7. doi: 10.1111/anae.13502. Epub 2016 May 30.</citation>
    <PMID>27238859</PMID>
  </reference>
  <reference>
    <citation>Stokes AL, Adhikary SD, Quintili A, Puleo FJ, Choi CS, Hollenbeak CS, Messaris E. Liposomal Bupivacaine Use in Transversus Abdominis Plane Blocks Reduces Pain and Postoperative Intravenous Opioid Requirement After Colorectal Surgery. Dis Colon Rectum. 2017 Feb;60(2):170-177. doi: 10.1097/DCR.0000000000000747.</citation>
    <PMID>28059913</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>August 21, 2017</study_first_submitted>
  <study_first_submitted_qc>August 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2018</study_first_posted>
  <results_first_submitted>April 22, 2019</results_first_submitted>
  <results_first_submitted_qc>August 14, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 9, 2019</results_first_posted>
  <last_update_submitted>August 14, 2019</last_update_submitted>
  <last_update_submitted_qc>August 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bupivacaine</keyword>
  <keyword>Exparel</keyword>
  <keyword>TAP Block</keyword>
  <keyword>Opioids</keyword>
  <keyword>Narcotics</keyword>
  <keyword>ERAS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 26, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/35/NCT03638635/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were approached for consent in the hospital postoperatively to request the use of their data for research purposes.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Standard Bupivacaine</title>
          <description>Standard (0.25% bupivacaine) bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
Bupivacaine: Abdominal injection of bupivacaine into fascial layer.</description>
        </group>
        <group group_id="P2">
          <title>Bupivacaine Liposome</title>
          <description>Liposomal bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
Bupivacaine liposome: Abdominal injection of bupivacaine liposome into fascial layer.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Initial Hospitalization</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study terminated prematurely</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by study personnel</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-Up (30 Days After Discharge)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study terminated prematurely</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Bupivacaine</title>
          <description>Standard (0.25% bupivacaine) bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
Bupivacaine: Abdominal injection of bupivacaine into fascial layer.</description>
        </group>
        <group group_id="B2">
          <title>Bupivacaine Liposome</title>
          <description>Liposomal bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
Bupivacaine liposome: Abdominal injection of bupivacaine liposome into fascial layer.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="63"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.97" spread="16.25"/>
                    <measurement group_id="B2" value="60.04" spread="17.36"/>
                    <measurement group_id="B3" value="60.63" spread="16.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>In-hospital Postoperative Opioid Consumption</title>
        <description>Daily overall opioid use recorded as morphine equivalents</description>
        <time_frame>up to postoperative day 3 at 1 pm</time_frame>
        <population>The amount of in-hospital postoperative opioid consumption was going to be obtained from the charts, where it is recorded as standard of care. However, this study was terminated prematurely before data could be collected from the charts; therefore no data are available for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Bupivacaine</title>
            <description>Standard (0.25% bupivacaine) bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
Bupivacaine: Abdominal injection of bupivacaine into fascial layer.</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine Liposome</title>
            <description>Liposomal bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
Bupivacaine liposome: Abdominal injection of bupivacaine liposome into fascial layer.</description>
          </group>
        </group_list>
        <measure>
          <title>In-hospital Postoperative Opioid Consumption</title>
          <description>Daily overall opioid use recorded as morphine equivalents</description>
          <population>The amount of in-hospital postoperative opioid consumption was going to be obtained from the charts, where it is recorded as standard of care. However, this study was terminated prematurely before data could be collected from the charts; therefore no data are available for this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Score</title>
        <description>Recorded on a scale of 0 (No pain) to 10 (Worst possible pain)</description>
        <time_frame>Approximately every 6 hours through postoperative day 3 by 1 pm</time_frame>
        <population>Outcome data reported for patients with non-missing data. Pain scores presented are the first postoperative pain score per subject only due to missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Bupivacaine</title>
            <description>Standard (0.25% bupivacaine) bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
Bupivacaine: Abdominal injection of bupivacaine into fascial layer.</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine Liposome</title>
            <description>Liposomal bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
Bupivacaine liposome: Abdominal injection of bupivacaine liposome into fascial layer.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Score</title>
          <description>Recorded on a scale of 0 (No pain) to 10 (Worst possible pain)</description>
          <population>Outcome data reported for patients with non-missing data. Pain scores presented are the first postoperative pain score per subject only due to missing data.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O2" value="3" lower_limit="0" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Patient Mobilization</title>
        <description>Number of days from day of surgery until patient mobilization</description>
        <time_frame>From time of surgery until time of first patient ambulation post op. Assessed until date of discharge (usually up to 4 days after surgery).</time_frame>
        <population>Outcome data reported for subjects with non-missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Bupivacaine</title>
            <description>Standard (0.25% bupivacaine) bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
Bupivacaine: Abdominal injection of bupivacaine into fascial layer.</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine Liposome</title>
            <description>Liposomal bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
Bupivacaine liposome: Abdominal injection of bupivacaine liposome into fascial layer.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Patient Mobilization</title>
          <description>Number of days from day of surgery until patient mobilization</description>
          <population>Outcome data reported for subjects with non-missing data.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Return of Bowel Function</title>
        <description>Number of days from time of surgery until return of bowel function</description>
        <time_frame>From time of surgery until first time patient passes gas or stool per rectum or into ostomy bag. Assessed until date of discharge (usually up to 4 days after surgery).</time_frame>
        <population>Outcome data reported for subjects with non-missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Bupivacaine</title>
            <description>Standard (0.25% bupivacaine) bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
Bupivacaine: Abdominal injection of bupivacaine into fascial layer.</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine Liposome</title>
            <description>Liposomal bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
Bupivacaine liposome: Abdominal injection of bupivacaine liposome into fascial layer.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Return of Bowel Function</title>
          <description>Number of days from time of surgery until return of bowel function</description>
          <population>Outcome data reported for subjects with non-missing data.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="2"/>
                    <measurement group_id="O2" value="2" lower_limit="1" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Clear Liquid Diet</title>
        <description>Number of days from time of surgery until patient tolerates clear liquid diet</description>
        <time_frame>From time of surgery until first time patient tolerates clear liquids without nausea or vomiting. Assessed until date of discharge (usually up to 4 days after surgery).</time_frame>
        <population>Outcome data reported for subjects with non-missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Bupivacaine</title>
            <description>Standard (0.25% bupivacaine) bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
Bupivacaine: Abdominal injection of bupivacaine into fascial layer.</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine Liposome</title>
            <description>Liposomal bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
Bupivacaine liposome: Abdominal injection of bupivacaine liposome into fascial layer.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Clear Liquid Diet</title>
          <description>Number of days from time of surgery until patient tolerates clear liquid diet</description>
          <population>Outcome data reported for subjects with non-missing data.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Low Fiber Diet</title>
        <description>Number of days from day of surgery until patient tolerates low fiber diet</description>
        <time_frame>From time of surgery until first time patient tolerates a low fiber diet without nausea or vomiting. Assessed until date of discharge (usually up to 4 days after surgery).</time_frame>
        <population>Outcome data reported for subjects with non-missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Bupivacaine</title>
            <description>Standard (0.25% bupivacaine) bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
Bupivacaine: Abdominal injection of bupivacaine into fascial layer.</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine Liposome</title>
            <description>Liposomal bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
Bupivacaine liposome: Abdominal injection of bupivacaine liposome into fascial layer.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Low Fiber Diet</title>
          <description>Number of days from day of surgery until patient tolerates low fiber diet</description>
          <population>Outcome data reported for subjects with non-missing data.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1" upper_limit="2.25"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Stay</title>
        <description>Total postoperative hospital stay in days</description>
        <time_frame>Date of surgery to date of discharge (usually up to 4 days after surgery).</time_frame>
        <population>Outcome data reported for subjects with non-missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Bupivacaine</title>
            <description>Standard (0.25% bupivacaine) bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
Bupivacaine: Abdominal injection of bupivacaine into fascial layer.</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine Liposome</title>
            <description>Liposomal bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
Bupivacaine liposome: Abdominal injection of bupivacaine liposome into fascial layer.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Stay</title>
          <description>Total postoperative hospital stay in days</description>
          <population>Outcome data reported for subjects with non-missing data.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="3" upper_limit="5"/>
                    <measurement group_id="O2" value="3.5" lower_limit="3" upper_limit="5.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In-hospital Antiemetic Use</title>
        <description>Amount of ondansetron patient required postoperatively during hospital stay, in milligrams</description>
        <time_frame>Time of transfer to post operative suite to time of discharge (usually up to 4 days after surgery).</time_frame>
        <population>Outcome data reported for subjects with non-missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Bupivacaine</title>
            <description>Standard (0.25% bupivacaine) bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
Bupivacaine: Abdominal injection of bupivacaine into fascial layer.</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine Liposome</title>
            <description>Liposomal bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
Bupivacaine liposome: Abdominal injection of bupivacaine liposome into fascial layer.</description>
          </group>
        </group_list>
        <measure>
          <title>In-hospital Antiemetic Use</title>
          <description>Amount of ondansetron patient required postoperatively during hospital stay, in milligrams</description>
          <population>Outcome data reported for subjects with non-missing data.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="3.6"/>
                    <measurement group_id="O2" value="5.6" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complications</title>
        <description>Patient suffered a complication (infection, small bowel obstruction, dehydration, deep vein thrombosis/pulmonary embolism, anastomotic leak, cardiac arrest, stroke, sepsis) after surgery</description>
        <time_frame>Within 30 days of surgery</time_frame>
        <population>Complications data was going to be collected from chart review. However, the study was prematurely terminated before this data could be collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Bupivacaine</title>
            <description>Standard (0.25% bupivacaine) bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
Bupivacaine: Abdominal injection of bupivacaine into fascial layer.</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine Liposome</title>
            <description>Liposomal bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
Bupivacaine liposome: Abdominal injection of bupivacaine liposome into fascial layer.</description>
          </group>
        </group_list>
        <measure>
          <title>Complications</title>
          <description>Patient suffered a complication (infection, small bowel obstruction, dehydration, deep vein thrombosis/pulmonary embolism, anastomotic leak, cardiac arrest, stroke, sepsis) after surgery</description>
          <population>Complications data was going to be collected from chart review. However, the study was prematurely terminated before this data could be collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Readmissions</title>
        <description>Patient readmitted to hospital after discharge</description>
        <time_frame>Within 30 days of hospital discharge</time_frame>
        <population>Readmissions data was going to be collected from chart review. However, the study was prematurely terminated before this data could be collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Bupivacaine</title>
            <description>Standard (0.25% bupivacaine) bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
Bupivacaine: Abdominal injection of bupivacaine into fascial layer.</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine Liposome</title>
            <description>Liposomal bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
Bupivacaine liposome: Abdominal injection of bupivacaine liposome into fascial layer.</description>
          </group>
        </group_list>
        <measure>
          <title>Readmissions</title>
          <description>Patient readmitted to hospital after discharge</description>
          <population>Readmissions data was going to be collected from chart review. However, the study was prematurely terminated before this data could be collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality</title>
        <description>Patient death after surgery</description>
        <time_frame>Within 30 days of surgery</time_frame>
        <population>Mortality data was going to be collected from chart review. However, the study was prematurely terminated before this data could be collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Bupivacaine</title>
            <description>Standard (0.25% bupivacaine) bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
Bupivacaine: Abdominal injection of bupivacaine into fascial layer.</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine Liposome</title>
            <description>Liposomal bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
Bupivacaine liposome: Abdominal injection of bupivacaine liposome into fascial layer.</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality</title>
          <description>Patient death after surgery</description>
          <population>Mortality data was going to be collected from chart review. However, the study was prematurely terminated before this data could be collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospitalization Costs</title>
        <description>Total hospitalization costs per patient per this surgical encounter</description>
        <time_frame>From date of this surgical admission to date of this surgical discharge (usually up to 4 days after surgery).</time_frame>
        <population>Cost data was intended to be collected through the finance department at the end of the study. However, the study was terminated prematurely, so cost data is not able to be obtained.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Bupivacaine</title>
            <description>Standard (0.25% bupivacaine) bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
Bupivacaine: Abdominal injection of bupivacaine into fascial layer.</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine Liposome</title>
            <description>Liposomal bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
Bupivacaine liposome: Abdominal injection of bupivacaine liposome into fascial layer.</description>
          </group>
        </group_list>
        <measure>
          <title>Hospitalization Costs</title>
          <description>Total hospitalization costs per patient per this surgical encounter</description>
          <population>Cost data was intended to be collected through the finance department at the end of the study. However, the study was terminated prematurely, so cost data is not able to be obtained.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days post-enrollment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Standard Bupivacaine</title>
          <description>Standard (0.25% bupivacaine) bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
Bupivacaine: Abdominal injection of bupivacaine into fascial layer.</description>
        </group>
        <group group_id="E2">
          <title>Bupivacaine Liposome</title>
          <description>Liposomal bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
Bupivacaine liposome: Abdominal injection of bupivacaine liposome into fascial layer.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <description>Return to the operating room</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination due to lack of resources leading to incomplete data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Erica Emery</name_or_title>
      <organization>Inova Health System</organization>
      <phone>703-776-7615</phone>
      <email>erica.emery@inova.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

